CA2208719A1 - Greffe de cellules hematopoietiques d'un primate donneur a un primate receveur - Google Patents

Greffe de cellules hematopoietiques d'un primate donneur a un primate receveur

Info

Publication number
CA2208719A1
CA2208719A1 CA002208719A CA2208719A CA2208719A1 CA 2208719 A1 CA2208719 A1 CA 2208719A1 CA 002208719 A CA002208719 A CA 002208719A CA 2208719 A CA2208719 A CA 2208719A CA 2208719 A1 CA2208719 A1 CA 2208719A1
Authority
CA
Canada
Prior art keywords
primate
cells
human
hematopoietic
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002208719A
Other languages
English (en)
Inventor
Yair Reisner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2208719A1 publication Critical patent/CA2208719A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé pour remplacer un système hématopoïétique d'un primate par un système hématopoïétique provenant d'un autre primate d'une espèce différente.
CA002208719A 1994-12-22 1995-12-22 Greffe de cellules hematopoietiques d'un primate donneur a un primate receveur Abandoned CA2208719A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11210994A IL112109A0 (en) 1994-12-22 1994-12-22 Engraftment of hematopoietic cells from a primate donor to a primate recipient
IL112109 1994-12-22

Publications (1)

Publication Number Publication Date
CA2208719A1 true CA2208719A1 (fr) 1996-07-04

Family

ID=11066915

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002208719A Abandoned CA2208719A1 (fr) 1994-12-22 1995-12-22 Greffe de cellules hematopoietiques d'un primate donneur a un primate receveur

Country Status (5)

Country Link
EP (1) EP0820309A2 (fr)
JP (1) JPH10511552A (fr)
CA (1) CA2208719A1 (fr)
IL (1) IL112109A0 (fr)
WO (1) WO1996019965A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1109545C (zh) * 1996-12-13 2003-05-28 科学与工业研究会 螯合铁的制剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69131331T2 (de) * 1990-01-15 2000-03-02 Yeda Research And Development Co., Ltd. Dauerhafte Verpflanzung und Entwicklung menschlicher hämatopoietischer Zellinien bei normalen Säugetieren
EP0517199A1 (fr) * 1991-06-04 1992-12-09 Yeda Research And Development Company, Ltd. Transplantation durable de cellules et de tissu humain dans des mammifères normaux
IL107483A0 (en) * 1993-11-03 1994-02-27 Yeda Res & Dev Bone marrow transplantation

Also Published As

Publication number Publication date
WO1996019965A2 (fr) 1996-07-04
WO1996019965A3 (fr) 1996-09-06
IL112109A0 (en) 1995-03-15
EP0820309A2 (fr) 1998-01-28
JPH10511552A (ja) 1998-11-10

Similar Documents

Publication Publication Date Title
Koo et al. The NK-1.1 (-) mouse: a model to study differentiation of murine NK cells.
JP3784063B2 (ja) 異種移植耐性の増強およびブタサイトカイン
Sentman et al. Identification of a subset of murine natural killer cells that mediates rejection of Hh-1d but not Hh-1b bone marrow grafts.
Minato et al. On the heterogeneity of murine natural killer cells.
Bachar-Lustig et al. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
Cuchens et al. Phylogeny of lymphocyte heterogeneity: II. Differential effects of temperature on fish T-like and B-like cells
Miler et al. The immunological significance of the thymus
DE60026166T2 (de) Vetozellen die wirksam in der prävention von transplantatabstossung sind und kein graft-versus-host potential aufweisen
Flowers et al. Long-term transplantation of canine keratinocytes made resistant to G418 through retrovirus-mediated gene transfer.
Craddock et al. Circulating stem cells in mice treated with cyclophosphamide
Morikawa et al. The Role of Antigen-Presenting Cells in the Regulation of Delayed-Type Hypersensitivity: II. Epidermal Langerhans' Cells and Peritoneal Exudate Macrophages
Kedar et al. In vitro induction of cell-mediated immunity to murine leukemia cells. II. Cytotoxic activity in vitro and tumor-neutralizing capacity in vivo of anti-leukemia cytotoxic lymphocytes generated in macrocultures
Robinson et al. Evidence for a qualitative hierarchy within the Hoechst-33342 ‘side population’(SP) of murine bone marrow cells
Zeis et al. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1-and Th2-type CD4^+ T cells in mice
Limpens et al. Alterations in dendritic cell phenotype and function associated with immunoenhancing effects of a subcutaneously administered cyclophosphamide derivative
CA2208719A1 (fr) Greffe de cellules hematopoietiques d'un primate donneur a un primate receveur
Tai et al. Differential natural killer cell reactivity against T cell lymphomas by cells from normal or stimulated mice.
Ullrich et al. Specific suppression of allograft rejection after treatment of recipient mice with ultraviolet radiation and allogeneic spleen cells
Sabel et al. Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice
Karpenko et al. Nestin-GFP transgene labels immunoprivileged bone marrow mesenchymal stem cells in the model of ectopic foci formation
US6551589B1 (en) Method of reducing the chance of attack of cells in a body by the cellular immune systems
Heslop et al. Gene-marking and haemopoietic stem-cell transplantation
Garcia-Giralt et al. Extraction from bovine spleen of immunosuppressant with no activity on hematopoietic spleen colony formation
Touraine Cooperation between thymus and transplanted precursor cells during reconstitution of immunodeficiencies with bone marrow or fetal liver cells
UEDA et al. DIFFERENTIAL EFFECTS OF INTERLEUKIN 2 RECEPTOR-TARGETED THERAPY ON HEART AND KIDNEY ALLOGRAFTS IN RATS: DEPRESSION OF EFFECTIVENESS OF ART-18 MONOCLONAL ANTIBODY TREATMENT BY UREMIA

Legal Events

Date Code Title Description
FZDE Discontinued